BioSphere Medical, Inc. (BSMD) - Financial and Strategic Analysis Review

Document Sample
BioSphere Medical, Inc. (BSMD) - Financial and Strategic Analysis Review Powered By Docstoc
					             BioSphere Medical, Inc. (BSMD) - Financial and Strategic Analysis
                                         Review

       Reference Code: GDPH1187FSA                                                                                    Publication Date: SEP 2010

       1050 Hingham Street                Phone           +1 781 6817900                           Revenue           31.4 (million USD)
       Rockland, MA                       Fax             +1 781 7922745                           Net Profit        -2.67 (million USD)
       02370                              Website         www.biospheremed.com                     Employees         88
       United States                      Exchange        BSMD [NASDAQ]                            Industry          Pharmaceuticals & Healthcare

      Company Overview
       BioSphere Medical, Inc. (BioSphere) is a medical device company engaged in the development, manufacture and marketing of
       products using embolotherapy techniques. The company’s technologies contain patented bioengineered polymers, which are
       chemical compounds created through the application of medical science, engineering principles and manufacturing methods.
       These core technologies are used to produce miniature spherical embolic particles, or microspheres, that are designed to have
       uniquely beneficial properties for a variety of medical applications. The major embolic products of the company include
       Embosphere, Embo Gold Microspheres and Microspheres.

      Key Executives                                                            SWOT Analysis
                    Name                                  Title                 BioSphere Medical, Inc., SWOT Analysis
      David P. Southwell                   Chairman                             Strengths                   Weaknesses

      Richard J. Faleschini                Chief Executive Officer
                                                                                                                    Declining Market Share in
                                                                                Strong Liquidity Position
      John Mackinnon                       Director                                                                 Sector
      Timothy J. Barberich                 Director                             Consistent Performance of
                                                                                                                    Pending Lawsuits against
      William M. Cousins, Jr.              Director                             Microsphere Products
                                                                                                                    BioSphere Medical
      Source: Annual Report, Company Website, Primary and Secondary Research
      GlobalData

      Share Data                                                                Opportunities                       Threats
       BioSphere Medical, Inc.
       Share Price (USD) as on 08-Sep-                                   4.40   Emerging Markets                    Dependence on Limited
       2010                                                                                                         Suppliers
                                                                        -0.18   Changing Demographics
       EPS (USD)
                                                                                                                    Tightening of the FDA’s
       Market Cap (million USD)                                            82                                       Regulatory Oversight
       Enterprise Value (million USD)                                      70

       Shares Outstanding (million)                                        19
       Source: Annual Report, Company Website, Primary and Secondary Research   Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData                                                               GlobalData


      Financial Performance                                     
				
DOCUMENT INFO
Description: BioSphere Medical, Inc. (BioSphere) is a medical device company engaged in the development, manufacture and marketing of products using embolotherapy techniques. The company’s technologies contain patented bioengineered polymers, which are chemical compounds created through the application of medical science, engineering principles and manufacturing methods. These core technologies are used to produce miniature spherical embolic particles, or microspheres, that are designed to have uniquely beneficial properties for a variety of medical applications. The major embolic products of the company include Embosphere, Embo Gold Microspheres and Microspheres. BioSphere Medical, Inc. Key Recent Developments Sep 03, 2010 BioSphere Agrees To Settle Suit Over Merit Medical merger Jul 23, 2010 BioSphere Names In Class Action By Shareholders: SEC Filing Feb 10, 2010 BioSphere Reports Total Revenues Of $31.4 Million In 2009 Feb 01, 2010 BioSphere Medical Announces Retirement Of William M. Cousins From Its Board Oct 28, 2009 BioSphere Reports Revenues Of $7.7 Million In Q3 2009 This comprehensive SWOT profile of BioSphere Medical, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including, - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the comp
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.